EP4081514A1 — Btk inhibitors
Assigned to Biogen MA Inc · Expires 2022-11-02 · 4y expired
What this patent protects
Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 11A , R 11B , R 12 ,R 1 , R 11 , A 1 , A 2 , Q 1 , Q 2, Q 3 , X, W, and n are as defined herein; pharmaceutical compositions comprising said co…
USPTO Abstract
Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 11A , R 11B , R 12 ,R 1 , R 11 , A 1 , A 2 , Q 1 , Q 2, Q 3 , X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.